NM28-2746 / Numab, 3SBio - LARVOL DELTA

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin. (PubMed, Oncoimmunology) - "In xenograft models, NM28-2746 exhibited significant tumor suppressing activity, which was significantly enhanced by combination therapy with NM21-1480. NM28-2746, alone or in combination with NM21-1480, may overcome shortcomings of previous MSLN-targeted immuno-oncology drugs, exhibiting enhanced discrimination of high MSLN-expressing cell activity in the presence of sMSLN."

IO biomarker • Journal • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • Transplantation • MSLN

NM28-2746, a reduced affinity bivalent mesothelin-binding MATCH4 T cell engager, with half-life extension, increases selectivity for killing of mesothelin-overexpressing cells (AACR 2022) - "We also demonstrate dose dependent anti-tumor activity in in vivo efficacy studies in PBMC-reconstituted mice, and combination therapeutic activity with an anti-PD-L1, anti-4-1BB bispecific molecule (NM21-1480). Collectively, these data demonstrate an increased selectivity to mesothelin-overexpressing cells by this novel MATCH4 reduced affinity bivalent T cell engager. These data indicate the potential of this molecule to increase the therapeutic window by reducing safety concerns on normal tissue where mesothelin expression is low, and yet promote cytotoxicity on mesothelin over-expressing cancer cells."

IO biomarker • Oncology • MSLN

Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28 (Businesswire) - “Numab Therapeutics AG (Numab) and 3SBio Inc. ('3SBio', HKEX:1530) announced today that 3SBio’s subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ('Sunshine Guojian') exercised its option for an exclusive regional license for the development and commercialization of NM28, a potential best-in-class bivalent mesothelin (MSLN)-targeting CD3 T cell engager. Under the terms of this collaboration, which builds on the existing relationship between the two parties established in 2019, Sunshine Guojian will have exclusive rights to develop and commercialize NM28 in the Greater China area, including mainland China, Hong Kong, Macao and Taiwan. Numab retains NM28 rights for the rest of the world.”

Licensing / partnership • Oncology